| May 20 |
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit
|
| May 14 |
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning
|
| May 7 |
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
|
| May 2 |
NeuroSense Announces First Quarter 2024 Business Update
|
| Apr 22 |
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
|
| Apr 18 |
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
|
| Apr 12 |
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
|
| Apr 11 |
NeuroSense Therapeutics sheds 6% on $4.5M direct private offering
|
| Apr 10 |
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
|
| Apr 9 |
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
|
